NCT01439568

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

A Randomized Phase 2 Study of LY2510924 and Carboplatin/Etoposide Versus Carboplatin/Etoposide in Extensive-Stage Small Cell Lung Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to compare the progression free survival of LY2510924 + carboplatin + etoposide therapy versus carboplatin + etoposide therapy in participants with extensive-stage disease small cell lung cancer (SCLC)

Conditions

• Extensive Stage Small Cell Lung Carcinoma

Interventions

Type	Name	Description
DRUG	LY2510924	Administered subcutaneous injection
DRUG	Carboplatin	Administered intravenously
DRUG	Etoposide	Administered intravenously

Timeline

• Start date: 2011-09-01
• Primary completion: 2014-01-01
• Completion: 2016-08-01
• First posted: 2011-09-23
• Last updated: 2019-07-23
• Results posted: 2019-07-23

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated drug study